Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
European Journal of Pharmacology
|
May 8, 2010
Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation
Karin J Stebbins, Alex R Broadhead, Lucia D Correa, et al.
Clinical and Diagnostic Laboratory Immunology
|
September 3, 1999
Mastitis and immunological factors in breast milk of lactating women in Malawi
R D Semba, N Kumwenda, T E Taha, et al.
International Archives of Allergy and Immunology
|
November 2, 2011
DP2 (CRTh2) antagonism reduces ocular inflammation induced by allergen challenge and respiratory syncytial virus
Karin J Stebbins, Alexander R Broadhead, Alla Musiyenko, et al.
Journal of Human Lactation : Official Journal of International Lactation Consultant Association
|
April 25, 2000
Mastitis and immunological factors in breast milk of human immunodeficiency virus-infected women
R D Semba, N Kumwenda, T E Taha, et al.
The Journal of Infectious Diseases
|
June 3, 1999
Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1
R D Semba, N Kumwenda, D R Hoover, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 14, 2011
Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation
Gretchen Bain, Daniel S Lorrain, Karin J Stebbins, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 15, 2009
Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation
Daniel S Lorrain, Gretchen Bain, Lucia D Correa, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 31, 2024
Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis
Michael M Poon, Kym I Lorrain, Karin J Stebbins, et al.
Scientific Reports
|
May 8, 2024
Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis
Michael M Poon, Kym I Lorrain, Karin J Stebbins, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
December 10, 2009
Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lung
Karin J Stebbins, Alex R Broadhead, Christopher S Baccei, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
European Journal of Pharmacology
|
May 8, 2010
Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation
Karin J Stebbins, Alex R Broadhead, Lucia D Correa, et al.
Clinical and Diagnostic Laboratory Immunology
|
September 3, 1999
Mastitis and immunological factors in breast milk of lactating women in Malawi
R D Semba, N Kumwenda, T E Taha, et al.
International Archives of Allergy and Immunology
|
November 2, 2011
DP2 (CRTh2) antagonism reduces ocular inflammation induced by allergen challenge and respiratory syncytial virus
Karin J Stebbins, Alexander R Broadhead, Alla Musiyenko, et al.
Journal of Human Lactation : Official Journal of International Lactation Consultant Association
|
April 25, 2000
Mastitis and immunological factors in breast milk of human immunodeficiency virus-infected women
R D Semba, N Kumwenda, T E Taha, et al.
The Journal of Infectious Diseases
|
June 3, 1999
Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1
R D Semba, N Kumwenda, D R Hoover, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 14, 2011
Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation
Gretchen Bain, Daniel S Lorrain, Karin J Stebbins, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 15, 2009
Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation
Daniel S Lorrain, Gretchen Bain, Lucia D Correa, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 31, 2024
Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis
Michael M Poon, Kym I Lorrain, Karin J Stebbins, et al.
Scientific Reports
|
May 8, 2024
Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis
Michael M Poon, Kym I Lorrain, Karin J Stebbins, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
December 10, 2009
Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lung
Karin J Stebbins, Alex R Broadhead, Christopher S Baccei, et al.
Page
of 5